[The role of biomedical interventions in HIV prevention: Pre-exposure Prophylaxis (PrEP)]

Semergen. 2020 Apr;46(3):202-207. doi: 10.1016/j.semerg.2019.06.006. Epub 2019 Aug 5.
[Article in Spanish]

Abstract

HIV infection remains an important public health problem worldwide. The traditional preventive measures, such as sexual education, screening, and early antiretroviral treatment initiation, despite having shown their effectiveness, are not enough to control new infections. In this context, Pre-Exposure Prophylaxis (PrEP) has been investigated as a preventive measure. Currently, it has been extensively documented that the administration of antiretroviral treatment in an HIV exposed, but not infected population, could reduce the risk of transmission without significant drawbacks. Despite its high efficacy for HIV prevention, the use of PrEP remains a controversial measure, particularly its cost-effectiveness. For this reason, the access to PrEP is not available for all the HIV risk groups. Therefore, and based on the evidence found, the current approach must be the repercussions of not to implement PrEP, more than its cost or its effectiveness.

Keywords: Human immunodeficiency virus; Pre-exposure prophylaxis; Prevención; Prevention; Profilaxis preexposición; Public health; Salud pública; Virus de inmunodeficiencia humana.

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Cost-Benefit Analysis
  • HIV Infections*
  • Humans
  • Pre-Exposure Prophylaxis*
  • Sexual Behavior

Substances

  • Anti-HIV Agents